Skip to main content
. 2022 Sep 16;12:15593. doi: 10.1038/s41598-022-18716-5

Figure 1.

Figure 1

Outline of trial design. Bev: Bevacizumab; Car: Carboplatin; Pac: Paclitaxel, MAb: Experimental antibody; C1D1: Cycle 1 day 1; C2D1: Cycle 2 day 1; Q21D: Dose administered every 21 days; * Sample collected prior to dosing.